ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 60 citations in OpenAlex.
- Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.The Journal of clinical investigation · 2026Review
- Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy.Cell reports. Medicine · 2026Article
- Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes.Frontiers in immunology · 2026Review
- Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.Journal of nanobiotechnology · 2025Article
- Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities.Clinical & translational immunology · 2025Review
- OX40/OX40L: a new target for tumor immunotherapy and its clinical research progress.Frontiers in oncology · 2025Review
- Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy.Therapeutic advances in medical oncology · 2025Review
- Melanoma Derived Exosomes Amplify Radiotherapy Induced Abscopal Effect via IRF7/I-IFN Axis in Macrophages.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.Frontiers in oncology · 2024Article
- Design of a single-center, phase II trial to explore the efficacy and safety of 'R-ISV-RO' treatment in advanced tumors.Future oncology (London, England) · 2024Article
- An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.Future oncology (London, England) · 2024Article
- Immunologically relevant effects of radiation therapy on the tumor microenvironment.Essays in biochemistry · 2023Article
- Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy.Journal of translational medicine · 2023Article
- Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.Cancer immunology, immunotherapy : CII · 2023Article
- Heterogeneity and subtypes of CD4Frontiers in immunology · 2023Review
- Tumor-infiltrating OX40Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field.Cancers · 2022Article
- Article
- Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.International journal of molecular sciences · 2022Article
- High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Sharareh Niknam *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hampartsoum B Barsoumian *Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jonathan E SchoenhalsDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Heather L JacksonImmuno-oncology and combinations DPU, GlaxoSmithKline, Collegeville, Pennsylvania.
Niranjan YanamandraImmuno-oncology and combinations DPU, GlaxoSmithKline, Collegeville, Pennsylvania.
Mauricio S CaetanoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ailin LiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ahmed I YounesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alexandra CadenaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Taylor R CushmanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joe Y ChangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Quynh N NguyenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daniel R GomezDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adi DiabDepartment of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick HwuDepartment of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maria Angelica CortezDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
James W WelshDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwelsh@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USGlaxoSmithKline (United States) · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Agents, ImmunologicalCell Line, TumorChemoradiotherapyDisease Models, AnimalDose-Response Relationship, DrugDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingMiceProgrammed Cell Death 1 ReceptorReceptors, OX40T-Lymphocyte SubsetsXenograft Model Antitumor AssaysAntineoplastic Agents, ImmunologicalProgrammed Cell Death 1 ReceptorReceptors, OX40
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.